Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects
Saswata Talukdar, Yingjiang Zhou, Dongmei Li, et al.
Cell Metabolism (2016) Vol. 23, Iss. 3, pp. 427-440
Open Access | Times Cited: 440

Showing 1-25 of 440 citing articles:

Mechanisms of Insulin Action and Insulin Resistance
Max C. Petersen, Gerald I. Shulman
Physiological Reviews (2018) Vol. 98, Iss. 4, pp. 2133-2223
Open Access | Times Cited: 2196
Glucagon-like peptide 1 (GLP-1)
Timo D. Müller, Brian Finan, Stephen R. Bloom, et al.
Molecular Metabolism (2019) Vol. 30, pp. 72-130
Open Access | Times Cited: 1308
Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease
Alan Chait, Laura J. den Hartigh
Frontiers in Cardiovascular Medicine (2020) Vol. 7
Open Access | Times Cited: 1037
Anti-obesity drug discovery: advances and challenges
Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, et al.
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 3, pp. 201-223
Open Access | Times Cited: 700
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Paul J. Carter, Greg A. Lazar
Nature Reviews Drug Discovery (2017) Vol. 17, Iss. 3, pp. 197-223
Closed Access | Times Cited: 670
Targeting adipose tissue in the treatment of obesity-associated diabetes
Christine M. Kusminski, Perry E. Bickel, Philipp E. Scherer
Nature Reviews Drug Discovery (2016) Vol. 15, Iss. 9, pp. 639-660
Closed Access | Times Cited: 612
The endocrine function of adipose tissues in health and cardiometabolic disease
Ludger Scheja, Jöerg Heeren
Nature Reviews Endocrinology (2019) Vol. 15, Iss. 9, pp. 507-524
Closed Access | Times Cited: 508
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
Arun J. Sanyal, Edgar D. Charles, Brent A. Neuschwander‐Tetri, et al.
The Lancet (2018) Vol. 392, Iss. 10165, pp. 2705-2717
Closed Access | Times Cited: 460
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic
Leiluo Geng, Karen S.L. Lam, Aimin Xu
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 11, pp. 654-667
Closed Access | Times Cited: 448
Towards frailty biomarkers: Candidates from genes and pathways regulated in aging and age-related diseases
Ana L. Cardoso, Adelaide Fernandes, Juan Antonio Aguilar‐Pimentel, et al.
Ageing Research Reviews (2018) Vol. 47, pp. 214-277
Open Access | Times Cited: 396
An Integrated View of Immunometabolism
Yun Sok Lee, Joshua Wollam, Jerrold M. Olefsky
Cell (2018) Vol. 172, Iss. 1-2, pp. 22-40
Open Access | Times Cited: 373
Bile Acids as Metabolic Regulators and Nutrient Sensors
John Y.L. Chiang, Jessica M. Ferrell
Annual Review of Nutrition (2019) Vol. 39, Iss. 1, pp. 175-200
Open Access | Times Cited: 318
Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy
John Y.L. Chiang, Jessica M. Ferrell
AJP Gastrointestinal and Liver Physiology (2020) Vol. 318, Iss. 3, pp. G554-G573
Open Access | Times Cited: 298
FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms
Lucas D. BonDurant, Magdalene Ameka, Meghan C. Naber, et al.
Cell Metabolism (2017) Vol. 25, Iss. 4, pp. 935-944.e4
Open Access | Times Cited: 265
Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication
Jan‐Bernd Funcke, Philipp E. Scherer
Journal of Lipid Research (2019) Vol. 60, Iss. 10, pp. 1648-1697
Open Access | Times Cited: 259
FGF21 gene therapy as treatment for obesity and insulin resistance
Verónica Jiménez, Claudia Jambrina, Estefanía Casana, et al.
EMBO Molecular Medicine (2018) Vol. 10, Iss. 8
Open Access | Times Cited: 252
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Stephen A. Harrison, Peter Ruane, B. Freilich, et al.
Nature Medicine (2021) Vol. 27, Iss. 7, pp. 1262-1271
Open Access | Times Cited: 252
Fibroblast Growth Factor 21—Metabolic Role in Mice and Men
Harald Staiger, Michaela Keuper, Lucia Berti, et al.
Endocrine Reviews (2017) Vol. 38, Iss. 5, pp. 468-488
Open Access | Times Cited: 233
Pharmacotherapy of obesity: Available medications and drugs under investigation
Eleni Pilitsi, Olivia M. Farr, Stergios A. Pοlyzos, et al.
Metabolism (2018) Vol. 92, pp. 170-192
Open Access | Times Cited: 229
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Matthias H. Tschöp, Brian Finan, Christoffer Clemmensen, et al.
Cell Metabolism (2016) Vol. 24, Iss. 1, pp. 51-62
Open Access | Times Cited: 216
A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21
Steven A. Kliewer, David J. Mangelsdorf
Cell Metabolism (2019) Vol. 29, Iss. 2, pp. 246-253
Open Access | Times Cited: 216
The Role of Exercise in the Interplay between Myokines, Hepatokines, Osteokines, Adipokines, and Modulation of Inflammation for Energy Substrate Redistribution and Fat Mass Loss: A Review
Adrian M. González-Gil, Leticia Elizondo‐Montemayor
Nutrients (2020) Vol. 12, Iss. 6, pp. 1899-1899
Open Access | Times Cited: 210
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Rohit Loomba, Arun J. Sanyal, Kris V. Kowdley, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 11, pp. 998-1008
Open Access | Times Cited: 209
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Michael A. Nauck, Jakob Wefers, Juris J. Meier
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 8, pp. 525-544
Closed Access | Times Cited: 203
Metabolic Messengers: FGF21
Kyle H. Flippo, Matthew J. Potthoff
Nature Metabolism (2021) Vol. 3, Iss. 3, pp. 309-317
Open Access | Times Cited: 201
Page 1 - Next Page

Scroll to top